Company Analysis COSMOS Pharmaceutical Corporation
1. Summary
Advantages
- Current debt level 6.27% is below 100% and has decreased over 5 years from 6.86%.
- The company's current efficiency (ROE=10.57%) is higher than the sector average (ROE=-10.46%)
Disadvantages
- Price (13755 Β₯) is higher than fair price (3010.96 Β₯)
- Dividends (1.3%) are below the sector average (2.62%).
- The stock's return over the last year (-47.03%) is lower than the sector average (-5.32%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
COSMOS Pharmaceutical Corporation | Healthcare | Index | |
---|---|---|---|
7 days | -2% | -0% | 1% |
90 days | -42.9% | -0% | 7.9% |
1 year | -47% | -5.3% | 20.2% |
3349 vs Sector: COSMOS Pharmaceutical Corporation has significantly underperformed the "Healthcare" sector by -41.71% over the past year.
3349 vs Market: COSMOS Pharmaceutical Corporation has significantly underperformed the market by -67.21% over the past year.
Stable price: 3349 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 3349 with weekly volatility of -0.9045% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (13755 Β₯) is higher than the fair price (3010.96 Β₯).
Price is higher than fair: The current price (13755 Β₯) is 78.1% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (20.86) is lower than that of the sector as a whole (111.03).
P/E vs Market: The company's P/E (20.86) is lower than that of the market as a whole (101.86).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (2.2) is lower than that of the sector as a whole (70.29).
P/BV vs Market: The company's P/BV (2.2) is lower than that of the market as a whole (67.75).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0.5286) is lower than that of the sector as a whole (75.03).
P/S vs Market: The company's P/S indicator (0.5286) is lower than that of the market as a whole (67.66).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (9.56) is lower than that of the sector as a whole (76.71).
EV/Ebitda vs Market: The company's EV/Ebitda (9.56) is lower than that of the market as a whole (113.45).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 5.49% over the last 5 years.
Earnings Slowdown: The last year's return (2.76%) is below the 5-year average return (5.49%).
Profitability vs Sector: The return for the last year (2.76%) exceeds the return for the sector (-1.55%).
5.4. ROE
ROE vs Sector: The company's ROE (10.57%) is higher than that of the sector as a whole (-10.46%).
ROE vs Market: The company's ROE (10.57%) is higher than that of the market as a whole (2.63%).
5.5. ROA
ROA vs Sector: The company's ROA (5.13%) is higher than that of the sector as a whole (-10.03%).
ROA vs Market: The company's ROA (5.13%) is higher than that of the market as a whole (3.68%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (12.41%) is higher than that of the sector as a whole (9.09%).
ROIC vs Market: The company's ROIC (12.41%) is higher than that of the market as a whole (8.77%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 1.3% is below the average for the sector '2.62%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 1.3% has been steadily paid over the past 7 years, DSI=0.86.
Weak dividend growth: The company's dividend yield 1.3% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (19.05%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription